Announced Tue, 30 Jun · 15:59 IST

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.4%1-day move
₹808.35
prior close
₹815.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.3+0.0-0.5+1.4+1.8+1.1+0.9+0.7+2.1-12.0
Up moveDown movePending
AI summary

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received two drug license suspension orders from the Assistant Director, Drugs Control Administration, Circle Gadag, Karnataka. The suspensions are for one day each and apply to stores located at Gajendragad and College Road Gadag in Karnataka. The orders were received on June 29, 2026, under Rule 65 of the Drugs and Cosmetics Act, 1940. The financial impact is minimal, with a potential revenue loss of Rs 0.32 lakhs and Rs 0.47 lakhs for the two stores respectively. The disclosure was filed under SEBI Listing Regulations.

Likely market impact

The financial impact on Medplus is negligible given the very small revenue loss (under Rs 1 lakh total) from just two stores for a single day. This is a routine regulatory compliance disclosure with no material effect on the company's overall operations or financial position.